Andrew Walker

Andrew Walker

Equities remain near record highs even as the 10-year yield climbed from 4.2% to 5.1% by September 24, suggesting rates’ financial gravity may be operating with a long fuse.As 2021-23 debt reaches 2028-31 refinancing, replacing 3.5% coupons with 8-10% could expose overstated free cash flow, while higher discount rates reduce special-situation spreads and may leave a more brittle market.

Andrew Walker

With 10-year Treasuries and ERP around 4.5%, Walker warns that ERP returning to 6% could sharply compress P/E multiples.Higher rates could raise data-center lease requirements 5–10% and reduce 15-year contract terminal values, while tenant bankruptcy, Bitcoin-mining economics, or founder-driven capital allocation at UWMC and Cogent remain risks to monitor.

Andrew Walker × David Thomas

Fairfax delivered a 19.2% cumulative annual return from 1985 through 2024 as insurance, investments, and non-insurance operations evolved into three concurrent earnings engines after costly lessons in under-reserving and hedging.Buybacks have retired more than 20% of shares but recently slowed; succession and the 15% long-term book-value-growth objective now test whether this second wind can outlast Fairfax’s “seven lean years, seven fat years” rhythm.

Andrew Walker × Andrei Stetsenko

Maharashtra Scooters offers roughly $4 billion of listed Bajaj shares and no debt at about 50% of marked NAV, while earnings growth—not liquidation—underpins the thesis.Bajaj Finance and Bajaj Finserv provide exposure to underpenetrated lending, insurance, and asset management; SEBI reforms and Bajaj Holdings’ recent share sales could narrow the discount, but collection discipline and cyclical growth remain central risks.

Andrew Walker × Byrne Hobart

Early Buffett’s repeatable edge was “cigar butts plus control” or buying businesses amid company-specific distress, not simply owning mature compounders.Sanborn Map and Dempster Mill show activism and liquidation supplying the catalyst, while GEICO and The Washington Post illustrate crisis-created entry prices.Salomon and LTCM suggest crisis expertise could become valuable, but the missed roughly $3 billion immediate LTCM opportunity highlights execution risk.

Andrew Walker

Markets recovered from the roughly 10% “Liberation Day” drop, but delayed plants, stores, deals, and capital spending leave tariff policy and recession risk unresolved.AI may commoditize quantitative work and 10-K comparison, making judgment and real-time management assessment scarcer despite meetings that expose investors to elite salesmanship.Biotech optionality can vanish after 50% clinical odds, time discounting, trial costs, and roughly $50 million annual overhead when incentives favor continued spending.